possible without balancing its benefits for maintaining response with the price that must be paid. Hopefully, as new regimens and approaches are tested, these quality of life studies will be included at the onset. Thus, when final trial results are available, the clinician caring for the myeloma patient will be able to honestly and forthrightly discuss the complete ramifications of each therapeutic option.
To keep pace with this prodigious outpouring of new information, JNCCN is committed to publishing full updates of each of its guidelines on an every 2-to 3-year cycle. Because all guidelines are updated on an annual basis, we will also feature more frequent concise updates to alert readers that new findings have led to substantive changes. The reader can then access the full guideline at www.nccn.org to get a fuller explanation of the impact of the new trial results.
What exciting times we live in.
